Lilly to Buy Centessa for OX2R Sleep Drugs Eli Lilly announced acquisition of Centessa on Mar 31, 2026 (Investing.com). Narcolepsy prevalence estimated at ~0.05%; deal terms pending disclosure.

Lilly to Buy Centessa for OX2R Sleep Drugs: Eli Lilly announced acquisition of Centessa on Mar 31, 2026 (Investing.com). Narcolepsy prevalence estimated at ~0.05%; deal terms pending disclosure. 👈 Read full analysis #EliLilly #Centessa #SleepDrugs #Narcolepsy #OX2R

Divergent modulation of dopaminergic neurons by hypocretin/orexin receptors-1 and -2 shapes dopaminergic cell activity and socio-emotional behavior Many neuropsychiatric disorders involve dysregulation of the dopaminergic (DA) input to the forebrain. Of particular relevance are DA projections originating from the midbrain ventral tegmental area (...

Our follow-up study on the orexin↔dopamine neuronal interplay is here to share! We discover opposite action of #hypocretin/orexin A vs B via #OX1R vs #OX2R on VTADA cell excitability +demonstrate striking distinct impact of DA cell Ox1 vs 2R loss on mouse behavior in socioemotional&cognitive domain